We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
John H. Stone, MD, MPH
Yoh Zen, MD, PhD, FRCPath
Avinash Kambadakone-Ramesh, MD, DNB, FRCR
J. Matthias Löhr, MD
The Evolving Role of MET TKIs in NSCLC
Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Jyoti Patel, MD
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Interprofessional Coordination of Adverse Event Management
Maximizing Adherence and Persistence via Patient Engagement
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
Treatment Intensification in HR+/HER2- EBC: Who and When?
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
Recent updates from adjuvant trials in HR+/HER2- EBC
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
Emanuel Della Torre, MD, PhD
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Yasmin Genevieve Hernandez-Barco, MD
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education